Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P.

Rhea-AI Summary

Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT / 1:30 p.m. ET.

Investors can access presentation materials and slides on the company's investor relations events page at the time of posting.

Argus Jan 13 session

+0.63% close to close Open Argus

Details

News Market Reaction – DNA

In the Jan 13 session, DNA gained 0.63%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Ginkgo Bioworks’ participation in the 44th Annual J.P. Morgan Healthcar...

Analysis

This announcement highlights Ginkgo Bioworks’ participation in the 44th Annual J.P. Morgan Healthcare Conference, with management presenting on January 15, 2026. It follows a series of ARPA-H backed collaborations and government contracts, including a deal of up to $47M, underscoring a focus on platform partnerships. Investors may watch for any new disclosures from the presentation and monitor subsequent regulatory filings, given the active S-3 shelf and prior 424B5 prospectus supplement.

Key Figures

Conference date: January 15, 2026 Presentation time (PT): 10:30 a.m. PT Presentation time (ET): 1:30 p.m. ET

Conference date

January 15, 2026

J.P. Morgan Healthcare Conference presentation date

Presentation time (PT)

10:30 a.m. PT

Scheduled conference presentation time

Presentation time (ET)

1:30 p.m. ET

Scheduled conference presentation time

Historical Context

5 past events · Latest: Dec 22

5 events

1. Dec 22

   ARPA-H partnership

   24h Move

   +8.5%

   ARPA-H backed POSEIDON oncology screening partnership with Carnegie Mellon.

2. Dec 17

   Manufacturing collaboration

   24h Move

   -0.2%

   Collaboration with Agricen to optimize fermentation for soil amendment product.

3. Dec 09

   Drug safety platform

   24h Move

   +1.7%

   ARPA-H funded PREDICTS drug safety data platform with Deep Origin.

4. Dec 05

   DOE phenotyping contract

   24h Move

   +0.4%

   Four-year, up to $47M contract for high-throughput phenotyping platform.

5. Dec 03

   ARPA-H EMBODY support

   24h Move

   +4.9%

   Participation in STRM.BIO’s ARPA-H EMBODY-funded MV gene therapy program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT (1:30 p.m. ET).

Further details, including slides, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

About Ginkgo Bioworks

Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:
investors@ginkgobioworks.com 

MEDIA CONTACT:
press@ginkgobioworks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-the-44th-annual-jp-morgan-healthcare-conference-302659475.html

SOURCE Ginkgo Bioworks

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ginkgo Bioworks (DNA) present at the J.P. Morgan Healthcare Conference?

Jason Kelly will present on January 15, 2026 at 10:30 a.m. PT / 1:30 p.m. ET.

Who from Ginkgo Bioworks (DNA) is presenting at the January 2026 J.P. Morgan conference?

Co-Founder and CEO Jason Kelly is scheduled to present.

Where can investors find Ginkgo Bioworks (DNA) presentation slides from the J.P. Morgan conference?

Slides and further details will be posted on the company's investor relations events page.

Will Ginkgo Bioworks (DNA) provide a webcast or replay for the January 15, 2026 presentation?

The announcement states slides will be posted on the investor relations site; check that page for any webcast or replay details.

How should shareholders follow Ginkgo Bioworks (DNA) updates from the J.P. Morgan Healthcare Conference?

Monitor the company's investor relations events page for posted slides and any follow-up materials after the January 15, 2026 presentation.